TOP > 外国特許検索 > THERAPEUTIC AGENT FOR ARTERIOSCLEROSIS OR ARTERIOSCLEROTIC DISORDERS AND DIAGNOSTIC AGENT FOR ARTERIOSCLEROSIS OR ARTERIOSCLEROTIC DISORDERS

THERAPEUTIC AGENT FOR ARTERIOSCLEROSIS OR ARTERIOSCLEROTIC DISORDERS AND DIAGNOSTIC AGENT FOR ARTERIOSCLEROSIS OR ARTERIOSCLEROTIC DISORDERS UPDATE

外国特許コード F120006750
整理番号 S2011-0075
掲載日 2012年6月7日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2011JP076132
国際公開番号 WO 2012063955
国際出願日 平成23年11月8日(2011.11.8)
国際公開日 平成24年5月18日(2012.5.18)
優先権データ
  • 特願2010-249876 (2010.11.8) JP
  • 特願2011-153862 (2011.7.12) JP
発明の名称 (英語) THERAPEUTIC AGENT FOR ARTERIOSCLEROSIS OR ARTERIOSCLEROTIC DISORDERS AND DIAGNOSTIC AGENT FOR ARTERIOSCLEROSIS OR ARTERIOSCLEROTIC DISORDERS UPDATE
発明の概要(英語) The present invention ameliorates arteriosclerosis or arteriosclerotic disorders by means of a pharmacological mechanism that reduces the size of arteriosclerotic lesions. The following is included as an active ingredient: a complex comprising an antibody, which binds to folate receptor beta (FRβ), conjugated to a cytotoxin or cytotoxic agent; or said antibody.
従来技術、競合技術の概要(英語) BACKGROUND ART
And arteriosclerosis, cured and then thickened artery atherosclerosis atherosclerosis means, such as film curing in curing and arterioles are classified into. Among them atherosclerosis atherosclerosis is, to the inside wall of the artery atherosclerosis (plaque) (atherosclerosis) occurs in the raised, thickened artery means that the cured state. In addition, atherosclerotic disease is, various diseases caused by arteriosclerosis. Atherosclerotic disease, cerebral artery in a stroke or cerebral hemorrhage caused by arteriosclerosis, myocardial infarction or angina pectoris due to coronary arteries arteriosclerosis such as ischemic heart disease, aortic aneurysm or arteriosclerosis in the aorta due to aortic dissection, due to the renal artery sclerosis in the renal artery and renal failure caused thereby in a peripheral artery arteriosclerosis due to arteriosclerosis and the like can be exemplified. At present, for the treatment of atherosclerotic disease or arteriosclerosis, or atherosclerosis or atherosclerotic plaque such as reduced to stabilize the therapeutic agent is not efficacy, risk factors (hyperlipidemia, hypertension, obesity, diabetes) is given priority to improve. In addition, treatment of arteriosclerosis, for example of a narrow tube called a catheter through a blood vessel by inserting the instrument 'catheter operation', vascular atherosclerosis periphrastic made to rotate to the path of the 'bypass surgery' such as the surgical method may be employed. In addition, as the arteriosclerosis forming the, oxidized LDL membrane has been penetrated within the vessel undergoing degeneration, or via the macrophage scavenger receptor LDL and takes in the foam cells, macrophages and foam cells in atherosclerotic plaques due to the accumulation of which is assumed to be generated. However, the patent document 1, are involved in the metastasis of cancer growth and plays a central role in the inflammatory response responsible for 'cancer-associated macrophages localized cancerous tissue' targeted solid cancer therapeutic agents is disclosed. In addition, the patent document 1, solid cancer therapeutic agents as an example of the folate receptor (FR β) β cell an antibody which binds to a toxin or cytotoxic agent-conjugated complex disclosed can be used. This is, to localize to cancer tissues and cancer-associated macrophages expressed FR β, normal tissues do not express FR β is little are based on the findings that. In addition, patent document 2, non-patent document 1, and 2 is 3, a mouse monoclonal antibody anti-human FR β genes and the antigen recognition site of a modified form of Pseudomonas exotoxin (Pseudomonas aeruginosa exotoxin) gene fuzed to prepare a recombinant type immunotoxin, in a mouse model of rheumatoid arthritis synovial SCID -, for the selective removal of the immunotoxins FR β is expressed by macrophages, or effective in the treatment of rheumatoid arthritis, rheumatoid arthritis from macrophages observed differentiation into osteoclasts can inhibit angiogenesis and have been reported.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • 発明者(英語)
  • TEI, Chuwa
  • MIYATA, Masaaki
  • FURUSYO, Yuko
  • MATSUYAMA, Takami
  • NAGAI, Taku
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close